After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
We are very excited to launch our new website! Please take a few moments to click around and explore...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...